Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?

Ophthalmologica

Volumn 230, Issue 3, 2013, Pages 109-115

  Tomkins Netzer, Oren ^a,b   Taylor, Simon R J ^a,c   Lightman, Sue ^a,b,d  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Birdshot chorioretinopathy; CD20; Intra ocular inflammation; Remission; Rituximab; Uveitis

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TRIAMCINOLONE ACETATE; CD20 ANTIGEN;

ADULT; BEHCET DISEASE; BLOOD ANALYSIS; BONE DENSITY; CASE REPORT; CHILL; CHORIORETINOPATHY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEVER; FOLLOW UP; HEPATITIS B; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOENCEPHALOPATHY; LOCAL THERAPY; LYMPHOMA; MALE; RELAPSE; REMISSION; RETINA MACULA CYSTOID EDEMA; REVIEW; RIGOR; SCLERITIS; SEPTICEMIA; SERUM SICKNESS; SIDE EFFECT; UVEITIS; VISUAL ACUITY; VITRITIS; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; EYE DISEASE; GRANULOMATOSIS; INFECTION; MIDDLE AGED; NONHUMAN; NONINFECTIOUS UVEITIS; OPHTHALMOLOGICAL IMPLANT; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VITREORETINAL LYMPHOMA; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; UVEITIS;

EID: 84885101188     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000351426     Document Type: Review

References (62)

1. Larson T, Nussenblatt RB, Sen HN: Emerging drugs for uveitis. Exp Opin Emerg Drugs 2011; 16: 309-322.
2. Le Hoang P: The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol 2012; 51: 7-28.
3. Tomkins-Netzer O, Taylor SR, Lightman S: Corticosteroid-sparing agents: new treatment options. Dev Ophthalmol 2012; 51: 47-56.
4. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F: CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005; 4: 526-531. (Pubitemid 41415764)
5. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLADR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143-2159.
6. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-182. (Pubitemid 35279043)
7. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445. (Pubitemid 24030569)
8. Blank M, Shoenfeld Y: B cell targeted therapy in autoimmunity. J Autoimmun 2007; 28: 62-68. (Pubitemid 46680498)
9. Bonavida B: What signals are generated by anti-CD20 antibody therapy? Curr Hematol Malig Rep 2006; 1: 205-213. (Pubitemid 46092377)
10. Perosa F, Prete M, Racanelli V, Dammacco F: CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010; 267: 260-277.
11. Sadreddini S, Noshad H, Molaeefard M, Noshad R: Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol/Jpn Rheum Assoc 2008; 18: 306-308.
12. Arkfeld DG: The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008; 28: 205-215. (Pubitemid 350265480)
13. Cultrera JL, Dalia SM: Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 2012; 19: 204-213.
14. Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C: Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009; 8: 591-594.
15. Edwards JC, Leandro MJ, Cambridge G: B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 393-403, viii. (Pubitemid 38692569)
16. Kiely PD, Deighton C, Dixey J, Ostor AJ: Biologic agents for rheumatoid arthritis-negotiating the NICE technology appraisals. Rheumatology (Oxford) 2012; 51: 24-31.
17. Conti F, Perricone C, Ceccarelli F, Valesini G: Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010; 9: 716-720.
18. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45: 1432-1436. (Pubitemid 44605482)
19. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394-1400.
20. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim A, Le Guen J, Prud'homme A, Bienvenu B, de Menthon M, Camps S, Le Guen V, Aouba A, Cohen P, Mouthon L, Guillevin L: Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125-130.
21. Van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB: Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals of the Rheumatic Diseases, E-pub ahead of print.
22. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010; 69: 1629-1635.
23. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K: Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150. (Pubitemid 46226045)
24. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS: Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16: 1589-1599.
25. Ohguro N, Hashida N, Tano Y: Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 2008; 126: 1002-1003. (Pubitemid 352008390)
26. Freidlin J, Wong IG, Acharya N: Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 2007; 91: 1414. (Pubitemid 47492887)
27. Albert M, Beltran E, Martinez-Costa L: Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis (in Spanish). Arch Soc Esp Oftalmol 2011; 86: 118-120.
28. Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A: Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea 2010; 29: 708-710.
29. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1540-1547.
30. Onal S, Kazokoglu H, Koc A, Yavuz S: Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocular Immunology and Inflammation 2008; 16: 230-232.
31. Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005; 89: 1542. (Pubitemid 41527407)
32. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, Denisova RV, Chistyakova EG: Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011; 30: 1163-1172.
33. Narvaez J, Diaz-Torne C, Juanola X, Geli C, Llobet JM, Nolla JM, Diaz-Lopez C: Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68: 607-608.
34. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K: Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50: 1390-1394.
35. Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V: Rituximab for uveitis. Ophthalmology 2011; 118: 223-224.
36. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V: Anti-CD monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011; 11: 35-39.
37. Baslund B, Wiencke AK, Rasmussen N, Faurschou M, Toft PB: Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol 2012; 30: S7-S10.
38. Foster CS, Chang PY, Ahmed AR: Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117: 861-869.
39. Benitah NR, Sobrin L, Papaliodis GN: The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol 2011; 26: 295-303.
40. Evereklioglu C: Ocular Behcet disease: current therapeutic approaches. Curr Opin Ophthalmol 2011; 22: 508-516.
41. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N: Rituximab in intractable ocular lesions of Behcet's disease: randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13: 246-252.
42. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL: Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005; 64: 1087-1088. (Pubitemid 40909530)
43. Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR: Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 2011; 118: 2498-2503.
44. The Standardization of Uveitis Nomenclature (SUN) working group: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.
45. Davis JL: Intraocular lymphoma: a clinical perspective. Eye (Lond) 2013; 27: 153-162.
46. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Grillo-Lopez AJ, Wilson WH, Robinson MR: The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 2006; 82: 760-766. (Pubitemid 43170877)
47. Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD: Intraocular use of rituximab. Eye (Lond) 2007; 21: 1524-1527.
48. Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE: Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007; 18: 1851-1855. (Pubitemid 350111571)
49. Pe'er J, Hochberg FH, Foster CS: Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 2009; 17: 299-306.
50. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, Lamprecht P, Gross WL: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-858.
51. Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T: Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010; 18: 223-225.
52. Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ: Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 2009; 93: 984-985.
53. Kump LI, Castaneda RA, Androudi SN, Reed GF, Foster CS: Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006; 113: 1874-1877. (Pubitemid 44442436)
54. Gregory AC 2nd, Kempen JH, Daniel E, Kacmaz RO, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE: Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology 2013; 120: 186-192.
55. Browning JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006; 5: 564-576. (Pubitemid 43971191)
56. Lawrence JM 3rd, Moore TL, Osborn TG, Nesher G, Madson KL, Kinsella MB: Autoantibody studies in juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 22: 265-274. (Pubitemid 23065443)
57. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, Ponchel F, Emery P: Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-1279.
58. Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, Kai S: Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 89: 305-309.
59. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473.
60. Todd DJ, Helfgott SM: Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430-433.
61. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL: Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
62. Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ Jr: Hepatitis B reactivation and rituximab in the oncology practice. Oncologist 2010; 15: 1113-1121.